BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Moisturizing Effect of Two Dexpanthenol Formulations
Phase 2
Completed
- Conditions
- Skin Abnormalities
- Interventions
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19
- Registration Number
- NCT00839280
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
Completed
- Conditions
- HypogonadismParaplegiaBone DensityOsteoporosis
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2010-04-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT00838838
Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- Drug: Standard care treatment for VTE prophylaxisDrug: Rivaroxaban (Xarelto, BAY59-7939)
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19076
- Registration Number
- NCT00831714
A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs
Phase 3
Completed
- Conditions
- Infectious Diseases
- Interventions
- Drug: Avelox (Moxifloxacin, BAY12-8039)Drug: Amoxicilline/clavulanic
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT00828971
Hepatic Impairment Study
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45
- Registration Number
- NCT00829231
Safety of Gadovist in Renally Impaired Patients
Phase 4
Completed
- Conditions
- FibrosisRenal Impairment
- Interventions
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 927
- Registration Number
- NCT00828737
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
Phase 3
Completed
- Conditions
- Premenstrual Dysphoric Disorder ( PMDD)
- Interventions
- Drug: EE20/DRSP(YAZ, BAY86-5300)Drug: Placebo
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 187
- Registration Number
- NCT00824187
YAZ, Oral Contraceptive Registration in China
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: YAZ (SH T00186, BAY86-5300)
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 675
- Registration Number
- NCT00819312
GA YAZ ACNE in China Phase III
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: EE20/Drospirenone (YAZ, BAY86-5300)Drug: Placebo
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 179
- Registration Number
- NCT00818519
Naproxen Sodium ER Pharmacokinetic Study
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: Naproxen sodium ER (BAYH6689)Drug: Commercial Naproxen (Aleve, BAYH6689)
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT00818415
© Copyright 2025. All Rights Reserved by MedPath